RAYLA

Raymed Labs Share Price

₹3.17 +0.15 (4.97%)

28 Mar, 2025 20:31

SIP TrendupStart SIP in RAYLA

Start SIP

Performance

  • Low
  • ₹0
  • High
  • ₹0
  • 52 Week Low
  • ₹0
  • 52 Week High
  • ₹0
  • Open Price₹0
  • Previous Close₹0
  • Volume

Investment Returns

  • Over 1 Month + 10.07%
  • Over 3 Month + 10.07%
  • Over 6 Month + 20.99%
  • Over 1 Year + 45.41%
SIP Lightning

Smart Investing Starts Here Start SIP with Raymed Labs for Steady Growth!

Invest Now

Raymed Labs Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

Raymed Labs Financials

Raymed Labs Technicals

EMA & SMA

Current Price
₹3.17
+ 0.15 (4.97%)
  • stock-down_img
  • Bearish Moving Average 0
  • stock-up_img
  • Bullish Moving Average 0
  • 20 Day
  • ₹2.68
  • 50 Day
  • ₹2.41
  • 100 Day
  • ₹2.18
  • 200 Day
  • ₹2.37

Resistance and Support

3.17 Pivot Speed
  • R3 3.17
  • R2 3.17
  • R1 3.17
  • S1 3.17
  • S2 3.17
  • S3 3.17

What's your outlook on Raymed Labs?

You can only vote for once

Raymed Labs Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-01-27 Quarterly Results
2024-11-06 Quarterly Results
2024-08-12 Quarterly Results
2024-05-24 Audited Results
2024-02-06 Quarterly Results

Raymed Labs F&O

Raymed Labs Shareholding Pattern

No data available.

About Raymed Labs

  • NSE Symbol
  • RAYLA
  • BSE Symbol
  • 531207
  • ISIN
  • INE741C01017

Similar Stocks to Raymed Labs

Raymed Labs FAQs

Raymed Labs share price is ₹3 As on 28 March, 2025 | 20:17

The Market Cap of Raymed Labs is ₹1.4 Cr As on 28 March, 2025 | 20:17

The P/E ratio of Raymed Labs is -4 As on 28 March, 2025 | 20:17

The PB ratio of Raymed Labs is -0.6 As on 28 March, 2025 | 20:17

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23